| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 华海药业以人类健康事业为己任，致力于向全球患者提供高品质的医疗健康产品并不断提升产品的可及度，改善大众的生活质量。 华海药业创立于1989年，总部位于中国浙江。公司现有员工8000余人，在全球拥有40多家分子公司（包括中国、美国、德国等)﹔主要业务覆盖化学药、生物药、细胞治疗、贸易流通等多个领域，与全球近千家制药企业建立了长期稳定的合作关系，为100多个国家和地区提供医疗健康产品。 公司产品涵盖:心血管类、精神障碍类、神经系统类、抗感染类等领域，是全球主要的心血管、精神类健康医疗产品制造商之一。 作为中国医药国际化先导企业，华海药业是中国首家通过美国FDA制剂质量认证并自主拥有ANDA文号的制药公司，也是首家在美国实现规模化制剂销售的中国制药公司，在世界高端制药市场树立了中国制药品质形象。公司同时凭借自身国际化平台，以运筹全球市场的高度，引领中国制药冲出国门、走向世界，为中国医药行业的崛起而努力。 在中国，华海制剂产品已覆盖国内30多个省市。作为民族药企所肩负的使命，华海药业致力于为中国人民提供国际品质、国产价格的医疗健康产品,服务百姓健康。 | ||||||||||||||||||||||||
| Main Business | 从事多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 陈保华 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 祝永华 | ||||||||||||||||||||||||
| Solicitors | 浙江天册律师事务所 | ||||||||||||||||||||||||
| Auditors | 天健会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 057685991096 | ||||||||||||||||||||||||
| Fax No | 057685016010 | ||||||||||||||||||||||||
| Website | www.huahaipharm.com | ||||||||||||||||||||||||
| 600521@huahaipharm.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 04/03/2003 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.570 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.200 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 5.286 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 27.135B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |